Literature DB >> 8998871

Neuropathy secondary to pigmented villonodular synovitis of the hip.

A J Aboulafia1, L Kaplan, J Jelinek, J Benevenia, D K Monson.   

Abstract

Pigmented villonodular synovitis is a benign proliferative process of unknown origin that may cause extensive bone and joint destruction. Patients with this condition typically present with symptoms of mild discomfort and associated stiffness of the involved joint; however, the spectrum of presentations is broad. Although pigmented villonodular synovitis begins in, and usually is confined within, a synovium-lined joint, it may extend beyond the joint capsule and present as a soft tissue mass. Three cases of a previously unrecognized presentation of pigmented villonodular synovitis of the hip joint are presented. The authors believe these to be the first reported cases in the English language literature of pigmented villonodular synovitis of the hip seen with femoral or sciatic neuropathy.

Entities:  

Mesh:

Year:  1996        PMID: 8998871     DOI: 10.1097/00003086-199604000-00020

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  3 in total

1.  Pigmented villonodular synovitis responsive to imatinib therapy.

Authors:  Wynne M Snoots; David Watkins; Dee Dockery; Robert Mennel; Brennen Scott Cheek
Journal:  Proc (Bayl Univ Med Cent)       Date:  2011-04

2.  An unusual presentation of peroneal neuropathy secondary to pigmented villonodular synovitis: a case report.

Authors:  Zafer Orhan; Birhan Oktas; Umran Yildirim
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2009-02-10       Impact factor: 4.342

3.  Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol.

Authors:  Akihiko Takeuchi; Akihiro Nomura; Norio Yamamoto; Katsuhiro Hayashi; Kentaro Igarashi; Susumu Tandai; Akira Kawai; Akihiko Matsumine; Shinji Miwa; Yoshihiro Nishida; Tomoki Nakamura; Ryu Terauchi; Manabu Hoshi; Toshiyuki Kunisada; Makoto Endo; Kenichi Yoshimura; Toshinori Murayama; Hiroyuki Tsuchiya
Journal:  BMC Musculoskelet Disord       Date:  2019-02-09       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.